Glenmark Pharmaceuticals Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Updated: 23 Apr 2026 • 12:47 pm

Posted by:

Glenmark Pharmaceuticals Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

The Glenmark Pharmaceuticals share price target 2026 stands at Rs 1,512-1,732 as per analyst consensus — implying 20-38% upside from the current CMP of Rs 1,257. Investors tracking the Glenmark Pharmaceuticals share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Glenmark Pharmaceuticals (GLENMARK) achieves or misses this 12-month target. This article covers every dimension of the Glenmark Pharmaceuticals share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Glenmark Pharmaceuticals on Univest.

Table of Contents

Glenmark Pharmaceuticals Share Price Overview — April 2026

Company	Glenmark Pharmaceuticals
NSE Symbol	GLENMARK
Sector	Pharma / Domestic Brands / US Generics / Ichnos
CMP April 2026	Rs 1,257
52-Week High	Rs 1,757
52-Week Low	Rs 1,007
Market Cap	Rs 35,500 Cr
Trailing P/E	28x
Dividend FY26	Rs 3
Promoter Holding	46.7%
FII Holding	22.8%
12M Analyst Target	Rs 1,512-1,732
Upside from CMP	20-38%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Glenmark Pharmaceuticals price, FII/DII flows and analyst targets on the Univest Screener.

What Is Glenmark Pharmaceuticals?

Get Free Analyst Research on Glenmark Pharmaceuticals — Tap Here.

Glenmark Pharmaceuticals (NSE: GLENMARK) has a growing domestic branded portfolio (55% of revenues) and US generics. Ichnos Sciences NCE pipeline adds innovation optionality. Debt reduction is a key re-rating lever.

Budget 2026-27 Impact on Pharma

Budget 2026-27’s domestic pharma demand from healthcare coverage expansion benefits Glenmark’s India formulations growing 14% YoY.

Glenmark Pharmaceuticals share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 1,512	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 1,512-1,732	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 1,007 zone	FY27 miss and extended FII selling

Compare Glenmark Pharmaceuticals with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Glenmark Pharmaceuticals share price target 2026

1. India Pharma Sector — Structural Growth Tailwind

India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Glenmark Pharmaceuticals’s market position within this sector creates compounding runway that underpins the Glenmark Pharmaceuticals share price target 2026 consensus of Rs 1,512-1,732. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Glenmark Pharmaceuticals to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Glenmark Pharmaceuticals share price target 2026 consensus of Rs 1,512-1,732. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Glenmark Pharmaceuticals holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Glenmark Pharmaceuticals share price target 2026 of Rs 1,512-1,732.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Glenmark Pharmaceuticals’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Glenmark Pharmaceuticals share price target 2026 of Rs 1,512-1,732 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Glenmark Pharmaceuticals’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Glenmark Pharmaceuticals share price target 2026 bull case.

Download the Univest iOS App or Android App for live Glenmark Pharmaceuticals alerts and SEBI-registered research.

5 Risks That Could Impact the Glenmark Pharmaceuticals share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Glenmark Pharmaceuticals. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Glenmark Pharmaceuticals share price target 2026 consensus of Rs 1,512-1,732.

2. Valuation at 28x Requires Consistent Execution

At 28x trailing P/E, Glenmark Pharmaceuticals is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Glenmark Pharmaceuticals share price target 2026. The Rs 1,007 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma

Domestic and global competitors are investing aggressively in Glenmark Pharmaceuticals’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Glenmark Pharmaceuticals share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Glenmark Pharmaceuticals share price target 2026 of Rs 1,512-1,732.

5. FII Selling Risk — 22.8% Institutional Holding

With 22.8% FII ownership, Glenmark Pharmaceuticals is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Glenmark Pharmaceuticals share price target 2026 analyst consensus of Rs 1,512-1,732.

Glenmark Pharmaceuticals Bull Case vs Bear Case — Glenmark Pharmaceuticals share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	1,732	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 1,512-1,732	High	FY27 in-line earnings, stable macro
Bear Case	Rs 1,007 zone	Low	FY27 guidance cut, prolonged FII selling

Glenmark Pharmaceuticals Share Price Reference Table

NSE Symbol	GLENMARK
CMP	Rs 1,257
52-Week High	Rs 1,757
52-Week Low	Rs 1,007
Market Cap	Rs 35,500 Cr
P/E	28x
Promoter	46.7%
FII	22.8%
Dividend FY26	Rs 3
Short-Term Target	Rs 1,512
12M Target	Rs 1,512-1,732
Upside	20-38%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Glenmark Pharmaceuticals share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 1,508	FY27 earnings recovery and Pharma sector leadership
YES Securities	Buy	Rs 1,533	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 1,445	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Glenmark Pharmaceuticals.

How to Invest in Glenmark Pharmaceuticals — 5 Steps

Step 1: Research on the Univest Screener

Search GLENMARK on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Glenmark Pharmaceuticals share price target 2026.

Step 2: Identify Entry Level

Glenmark Pharmaceuticals at Rs 1,257 has key support near Rs 1,007. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Glenmark Pharmaceuticals share price target 2026 recovery is Rs 1,512.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 1,732 — the bull case for the Glenmark Pharmaceuticals share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Glenmark Pharmaceuticals share price target 2026.

Conclusion — Glenmark Pharmaceuticals share price target 2026

Glenmark Pharmaceuticals (GLENMARK) at Rs 1,257 offers 20-38% potential upside to the 12-month Glenmark Pharmaceuticals share price target 2026 consensus of Rs 1,512-1,732. The bull case to 1,732 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 1,007 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Glenmark Pharmaceuticals at current levels presents a monitored entry opportunity. For more Glenmark Pharmaceuticals share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Glenmark Pharmaceuticals share price target 2026

Q: What is Glenmark Pharmaceuticals share price target for 2026?

The 12-month Glenmark Pharmaceuticals share price target 2026 analyst consensus is Rs 1,512-1,732 — implying 20-38% upside from CMP Rs 1,257. Bull case: 1,732. Bear case: Rs 1,007 zone. Track the live Glenmark Pharmaceuticals share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Glenmark Pharmaceuticals a good buy at Rs 1,257?

This article does not constitute investment advice. At Rs 1,257, Glenmark Pharmaceuticals offers 20-38% upside to the Glenmark Pharmaceuticals share price target 2026 consensus of Rs 1,512-1,732. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Glenmark Pharmaceuticals 52-week high and low?

Glenmark Pharmaceuticals’s 52-week high is Rs 1,757 and 52-week low is Rs 1,007. At the current CMP of Rs 1,257, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Glenmark Pharmaceuticals share price target 2026 thesis.

Q: What sector is Glenmark Pharmaceuticals (GLENMARK) in?

Glenmark Pharmaceuticals operates in the Pharma / Domestic Brands / US Generics / Ichnos sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Glenmark Pharmaceuticals share price target 2026 bull case.

Q: What are the main risks for the Glenmark Pharmaceuticals share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 28x requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (22.8% holding). Monitor quarterly earnings closely.

Q: What is Glenmark Pharmaceuticals’s market cap?

Glenmark Pharmaceuticals has a market cap of Rs 35,500 Cr as of April 2026. At the Glenmark Pharmaceuticals share price target 2026 of Rs 1,512-1,732, the implied market cap would reflect 20-38% appreciation on the current base.

Q: What is Glenmark Pharmaceuticals dividend for FY26?

Glenmark Pharmaceuticals’s FY26 dividend is Rs 3. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Glenmark Pharmaceuticals share price target 2026 capital appreciation potential.

Q: How to buy Glenmark Pharmaceuticals shares?

Buy Glenmark Pharmaceuticals (GLENMARK) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 1,007 support zone, and download the Univest App for SEBI-registered research on the Glenmark Pharmaceuticals share price target 2026.